IRIS Accounts Production v24.3.0.553 08867450 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false Ordinary A 1.00000 Ordinary B 1.00000 Ordinary C 1.00000 Ordinary D 1.00000 Ordinary C 1.00000 Ordinary D 1.00000 1.00000 1.00000 76268 38610 80002 158976 37658 155242 76268 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh088674502023-03-31088674502024-03-31088674502023-04-012024-03-31088674502022-03-31088674502022-04-012023-03-31088674502023-03-3108867450ns15:EnglandWales2023-04-012024-03-3108867450ns14:PoundSterling2023-04-012024-03-3108867450ns10:Director12023-04-012024-03-3108867450ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3108867450ns10:SmallEntities2023-04-012024-03-3108867450ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3108867450ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3108867450ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3108867450ns10:FullAccounts2023-04-012024-03-3108867450ns10:OrdinaryShareClass12023-04-012024-03-3108867450ns10:OrdinaryShareClass22023-04-012024-03-3108867450ns10:OrdinaryShareClass32023-04-012024-03-3108867450ns10:OrdinaryShareClass42023-04-012024-03-3108867450ns10:OrdinaryShareClass332023-04-012024-03-31088674504ns10:OrdinaryShareClass42023-04-012024-03-310886745042ns10:Director22023-03-310886745042ns10:Director22022-03-310886745042ns10:Director22023-04-012024-03-310886745042ns10:Director22022-04-012023-03-310886745042ns10:Director22024-03-310886745042ns10:Director22023-03-3108867450ns5:CurrentFinancialInstruments2024-03-3108867450ns5:CurrentFinancialInstruments2023-03-3108867450ns5:ShareCapital2024-03-3108867450ns5:ShareCapital2023-03-3108867450ns5:RetainedEarningsAccumulatedLosses2024-03-3108867450ns5:RetainedEarningsAccumulatedLosses2023-03-3108867450ns10:RegisteredOffice2023-04-012024-03-3108867450ns5:ComputerEquipment2023-04-012024-03-3108867450ns5:ComputerEquipment2023-03-3108867450ns5:ComputerEquipment2024-03-3108867450ns5:ComputerEquipment2023-03-3108867450ns5:DeferredTaxation2023-04-012024-03-3108867450ns5:DeferredTaxation2024-03-3108867450ns10:OrdinaryShareClass12024-03-3108867450ns10:OrdinaryShareClass22024-03-3108867450ns10:OrdinaryShareClass32024-03-3108867450ns10:OrdinaryShareClass42024-03-3108867450ns10:Director22023-04-012024-03-31088674501ns10:Director12023-03-31088674501ns10:Director12022-03-31088674501ns10:Director12023-04-012024-03-31088674501ns10:Director12022-04-012023-03-31088674501ns10:Director12024-03-31088674501ns10:Director12023-03-31
REGISTERED NUMBER: 08867450 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2024

for

Bromage Urology Limited

Bromage Urology Limited (Registered number: 08867450)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Balance Sheet 1

Notes to the Financial Statements 3


Bromage Urology Limited (Registered number: 08867450)

Balance Sheet
31 March 2024

31.3.24 31.3.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 320 480

CURRENT ASSETS
Debtors 5 8,164 15,094
Cash at bank 349,557 276,434
357,721 291,528
CREDITORS
Amounts falling due within one year 6 182,065 103,874
NET CURRENT ASSETS 175,656 187,654
TOTAL ASSETS LESS CURRENT
LIABILITIES

175,976

188,134

PROVISIONS FOR LIABILITIES 7 61 -
NET ASSETS 175,915 188,134

CAPITAL AND RESERVES
Called up share capital 8 4 2
Retained earnings 175,911 188,132
SHAREHOLDERS' FUNDS 175,915 188,134

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Bromage Urology Limited (Registered number: 08867450)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 October 2024 and were signed on its behalf by:





Dr S J Bromage - Director


Bromage Urology Limited (Registered number: 08867450)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Bromage Urology Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 08867450

Registered office: SPACES Manchester
Peter House, Oxford Street
Manchester
M1 5AN

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 25% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Bromage Urology Limited (Registered number: 08867450)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 April 2023
and 31 March 2024 1,740
DEPRECIATION
At 1 April 2023 1,260
Charge for year 160
At 31 March 2024 1,420
NET BOOK VALUE
At 31 March 2024 320
At 31 March 2023 480

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 8,164 15,094

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Tax 25,503 26,526
Directors' current accounts 155,242 76,268
Accrued expenses 1,320 1,080
182,065 103,874

7. PROVISIONS FOR LIABILITIES
31.3.24 31.3.23
£    £   
Deferred tax 61 -

Deferred
tax
£   
Provided during year 61
Balance at 31 March 2024 61

Bromage Urology Limited (Registered number: 08867450)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.3.24 31.3.23
value: £    £   
1 Ordinary A £1 1 1
1 Ordinary B £1 1 1
1 Ordinary C £1 1 -
(31.3.23 -
NIL)
1 Ordinary D £1 1 -
(31.3.23 -
NIL)
4 2

Allotted and issued:
Number: Class: Nominal 31.3.24 31.3.23
value: £    £   
1 Share capital 3 £1 1 -
(31.3.23 -
NIL)
1 Share capital 4 £1 1 -
(31.3.23 -
NIL)
2 -

The following shares were issued during the year for cash at par :

1 Ordinary C share of £1
1 Ordinary D share of £1

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 March 2024 and 31 March 2023:

31.3.24 31.3.23
£    £   
Dr S J Bromage and Mrs E J Bromage
Balance outstanding at start of year (76,268 ) (38,610 )
Amounts advanced 80,002 -
Amounts repaid (158,976 ) (37,658 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (155,242 ) (76,268 )

Bromage Urology Limited (Registered number: 08867450)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

10. ULTIMATE CONTROLLING PARTY

The controlling party is the directors.